Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05226494 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety and Tolerability of Fb-PMT in Recurrent Glioblastoma

Name: Safety and Tolerability of Fb-PMT in Recurrent Glioblastoma — clinical trial record (NCT05226494)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 1

SponsorNanoPharmaceuticals LLC

Started2022-06-23

View on ClinicalTrials.gov ↗

Glioblastoma is a highly aggressive and fatal form of primary malignant brain tumor with limited treatment options. fb-PMT affects a large group of cancer cell signaling pathways and thus may be effective in heterogeneous, treatment-resistant tumors such as Glioblastoma. fb-PMT also is actively transported across the blood-brain barrier into the brain. This study is being conducted to determine the dose level for further clinical development of fb-PMT to treat recurrent Glioblastoma.

Amendment history 3 changes detected by DataLookout

2026-09-01

Enrollment closed, study ongoing

2026-09-01

Primary completion pushed: 2026-10 → 2027-06

2026-09-01

Completion pushed: 2027-10 → 2028-06

Trial Details

NCT Number	NCT05226494
Lead Sponsor	NanoPharmaceuticals LLC
Conditions	Glioma, Malignant
Enrollment	34 participants
Start Date	2022-06-23
Primary Completion	2027-06 (estimated)
Study Completion	2028-06 (estimated)
Updated on ClinicalTrials.gov	2026-08-31